Sign in4 stories
SPY003 hit its primary endpoint in SKYLINE Part A, joining SPY001 and SPY002 with positive monotherapy results ahead of combination-arm data expected in 2027.
SEC filing
Both doses hit statistical significance on some endpoints, but the effect size fell short of Spyre's bar to advance SPY072 as a standalone RA therapy.
SEC filing
Spyre says both antibodies hit primary and secondary endpoints in ulcerative colitis, while three SKYWAY sub-studies finished enrollment ahead of schedule.
SEC filing